Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Orexigen Therapeutics, Inc.

http://www.orexigen.com/

Latest From Orexigen Therapeutics, Inc.

Coronavirus Update: Will Moderna Really Demand Premium Price For COVID Vaccine?

There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.

Coronavirus COVID-19 Vaccines

Stem Cells For COVID-19: Promising Platform With A ‘Dark Side’

Mesenchymal stem cells have encouraging early data in ARDS, but the stem cell industry’s shady reputation complicates perception – and trial enrollment.

Regenerative Medicine Coronavirus COVID-19

Mesoblast, Athersys Take Lead In Race To Develop Stem Cell Therapies For COVID-19

Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.

Regenerative Medicine Coronavirus COVID-19

Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks

Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Orexigen Therapeutics Ireland Ltd.
UsernamePublicRestriction

Register